22.03.2024
GlaxoSmithKline Withdraws Inhaler Patents Amid FTC Crackdown on Non-Inventive Listings
In an unprecedented move, GlaxoSmithKline has retracted patent listings for Advair, Flovent, and Ventolin from the FDA’s Orange Book. This decision came after the FTC's scrutiny over non-inventive patent listings intensified, affecting several pharmaceutical companies aiming to maintain market exclusivity.
